FDA Watch: FDA Approves Enhanced Cologuard Cancer Test
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
Test maker Exact Sciences says it expects Cologuard Plus to cut false positives by more than 30 percent
From - National Intelligence Report
As a principle, it's hard to take issue with Science's recommendation; but as the article itself notes, actually achieving genomic data sharing remains…
By Steve Selbst bio
The purpose of this article is to help you, as a provider, to focus on three key items to look for in payer contracts that will help you to get profitable contracts in place…
From - National Intelligence Report
The opioid crackdown has made urine drug testing an even greater priority for federal health fraud enforcers. One principle target is specimen validity testing…
From - National Intelligence Report
The recent moves by CMS to include certain hospital outreach labs as "applicable laboratories" for purposes of PAMA reporting and…
From - National Intelligence Report
On Jan. 31, Department of Health and Human Services Secretary Alex Azar floated a proposed rule to…
From - National Intelligence Report
While everybody agrees that the FDA 510(k) premarket review pathway is antiquated and in desperate need of an overhaul…
From - National Intelligence Report
The federal Office for Civil Rights (OCR) reports that 2018 was a record year for HIPAA enforcement, with 10 settlements and one judgment bringing in…